ArticleIranian journal of parasitology
Construction of an Adenovirus Vaccine Expressing the Cross-reactive Antigen AMA1 for
Article in Iranian journal of parasitology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Studies on experimental animals immunized with different antigenic vaccine combinations of Neospora caninum of cattle origin.Parasites & vectors · 2025Article
- Recent Advances in the Development of Adenovirus-Vectored Vaccines for Parasitic Infections.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe aimed to construct an adenovirus expressing a cross-reactive fragment of the apical membrane antigen 1 (AMA1) antigen and evaluated the concomitant immune response in BABL/c mice, allowing protection against
methodsThe study was conducted in Agricultural College of Yanbian University, Yanji, Jilin, China In 2015-2016. Primers were designed using the AMA1 gene sequences of
resultsThe level of IgG in BABL/c mice immunized with Ad5-NcAMA1 was significantly increased when compared with that of pVAX1-NcAMA1 and PBS groups (
conclusionThe adenovirus vaccineAd5-NcAMA1 could provide protective immunity against
Indexed as
Identifiers
30069207PMC6068368What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.